Skip to main content

What the FDA labels say about taking them together

Pramlintide and repaglinide

Repaglinide's FDA label of May 2, 2025 names pramlintide in its drug interactions section; the pramlintide label PlainMeds reads does not name repaglinide. The repaglinide label: “… inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.”

Check it at the source: the pramlintide FDA label on DailyMed (effective December 18, 2019, AstraZeneca Pharmaceuticals LP); the repaglinide FDA label on DailyMed (effective May 2, 2025, Chartwell RX, LLC).

What does the pramlintide label say about repaglinide?

Pramlintide's label (effective December 18, 2019) does not name repaglinide in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (SymlinPen), AstraZeneca Pharmaceuticals LP, effective December 18, 2019 (SPL set 4aea30ff-eb0d-45c1-b114-3127966328ff), via openFDA; the full label on DailyMed

What does the repaglinide label say about pramlintide?

Repaglinide label, drug interactions

Drugs That May Increase the Risk of Hypoglycemia Intervention: Repaglinide tablets dose reductions and increased frequency of glucose monitoring may be required when co-administered. Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.

Source: FDA drug label (Repaglinide), Chartwell RX, LLC, effective May 2, 2025 (SPL set cb995e92-295e-4638-a064-978211f5afe1), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Pramlintide generic labelers
7Repaglinide generic labelers
PramlintideRepaglinide
Labeled forType 2 diabetes, Type 1 diabetesType 2 diabetes
Boxed warningYesNo
Pharmacy cost (NADAC)n/a$0.0987 per tablet 1 mg tablet
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?